Beauty

Shiseido to Sell China’s Aupres Business to IDG-Led Consortium

The Japanese group will transfer full ownership of Shiseido Liyuan Cosmetics, including its Beijing factory, while licensing IP and providing transition support.

Naomi SekiguchiNovember 19, 20265 min read2 views
An editorial illustration of an unlabeled skincare jar, production-line elements, a document folder and keys on a clean studio surface, suggesting a corporate handover in cosmetics manufacturing.

Shiseido has signed a binding agreement to sell its Chinese subsidiary, Shiseido Liyuan Cosmetics (SLC), to an investor consortium led by Hong Kong-based private equity firm IDG Capital. SLC makes and sells the Aupres brand in China. The Japanese cosmetics group did not disclose financial terms. The transaction is expected to close between the fourth quarter of 2026 and the first quarter of 2027, subject to regulatory approvals, including in China.

Under the deal, funds managed by IDG Capital will hold 95% of SLC’s equity through two special purpose vehicles. A limited partnership set up mainly by SLC’s new management team will hold the remaining 5%. The sale includes SLC’s Beijing factory and production equipment.

Transition support and licensing

Shiseido will license the intellectual property rights that IDG needs to run the business. For a specified period after the transfer, Shiseido will also provide support on new product development, technical assistance for the stable supply of existing products, and continued supply of raw materials and selected products. The company says the arrangements are intended to maintain SLC’s innovation capabilities, product quality and business continuity.

Joint venture history

SLC was established in 1991 as a joint venture with Beijing Liyuan, a subsidiary of Yiqing Group, which is owned by the Beijing Municipal Government. SLC has sold the C-beauty brand Aupres since 1994. With the current joint venture agreement due to expire in December 2026, the parties agreed not to renew it. On September 1, 2026, Shiseido acquired Beijing Liyuan’s 35% stake, giving it full ownership ahead of the sale.

Profitability and China strategy

The divestment is part of Shiseido’s push to improve profitability and capital efficiency under its 2030 Medium-Term Strategy. Shiseido says it wants to drive sustainable growth and strengthen its competitiveness in China by focusing management resources on areas where it “enjoys the greatest competitive advantage.” The sale allows the group to concentrate on priority brands and higher-growth opportunities, according to the company. Shiseido also says the business required continued investment in product innovation and digital capabilities.

Shiseido describes China as a strategically important and attractive, dynamic market. It says the competitive landscape continues to evolve amid rapid e-commerce expansion, changing consumer behavior and the emergence of diverse market participants.

Financial backdrop

The sale comes days after Shiseido reported a 124.3% jump in core operating profit for the third quarter of 2026, to ¥67.5 billion (US$422.13 million). The company attributed the recovery to restructuring, cost cuts and improved margins rather than strong product demand; like-for-like sales grew 0.7%. Shiseido raised its full-year core operating profit forecast from ¥59 billion (US$433 million) to ¥87 billion (US$546 million).